Researchers continue to excited about the medication , a novel dual agonist showing remarkable results in clinical trials for weight management. It acts by targeting several pathways : GLP-1 and GIP, that , when stimulated, help influence hunger and enhance energy expenditure . Preliminary observations suggest considerable body reduction and possib